Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis

Spessotto, Caroline Vieira; Cavalli, Hanaie; Eboni, Audred C. Biondo; Machado, Rafael Berlezi; Mousquer, Analara Munardi; Palazzo, Lara Both; Finkelsztejn, Alessandro; Gonçalves, Marcus Vinícius Magno; Sato, Henry Koiti; Siquineli, Fabio; Fragoso, Yára Dadalti

doi:10.1590/0004-282x20160091

Cited by 5 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The present study showed that half of the patients were satisfied or very satisfied with their treatment, whereas other authors 27 have indicated that over 80% of patients perceived treatment as beneficial. A study by Glanz et al 28 showed that for injections of interferon beta-1a administered subcutaneously, convenience and overall satisfaction with treatment were associated with decreased adherence.…”

Section: Discussioncontrasting

confidence: 74%

Adherence to disease-modifying therapies in patients with multiple sclerosis

Kołtuniuk¹,

Rosińczuk²

2018

PPA

View full text Add to dashboard Cite

BackgroundMultiple sclerosis (MS) is a chronic, inflammatory progressive demyelinating disease of the central nervous system. MS is one of the main causes of disability among young adults, and its management is a serious challenge for the healthcare system.PurposeThe main purpose of this study was to examine adherence to first-line disease-modifying therapy (DMT) in MS patients using the self-report Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ).Materials and methodsThe participants consisted of 226 MS patients (166 women and 60 men) who were treated with first-line immunomodulatory DMT. This study used a questionnaire designed by the authors, which contained questions about sociodemographic data, and the Polish version of the MS-TAQ.ResultsThe overall adherence was 76.5% according to the first criterion (missed ≥1 injection or tablet). There were no statistically significant differences due to sociodemographic variables between adherent and nonadherent patients. However, patients taking Avonex® significantly more often belonged to the adherent group (P=0.042). The most frequently mentioned reasons why nonadherent patients forget to take the drug included the following: too busy in their daily activities, indisposition to take the drug, unwillingness to take the drug, interference with daily activities, and dissatisfaction with the drug. The degree of adherence among MS patients treated with immunomodulatory drugs is high; however, some patients do not take medications regularly.ConclusionDue to the utility of the MS-TAQ, the caregivers of MS patients are able to quickly and easily assess the occurrence of side effects, ways to cope with them, and the occurrence of barriers to taking medication.

show abstract

Section: Discussioncontrasting

confidence: 74%

Adherence to disease-modifying therapies in patients with multiple sclerosis

Kołtuniuk¹,

Rosińczuk²

2018

PPA

View full text Add to dashboard Cite

show abstract

“…Responses were scored from 1 to 5 on a Likert scale, where (1) indicates "I do not agree at all," (2) indicates "I tend to disagree," (3) indicates "I have no opinion," (4) indicates "I tend to agree," and (5) indicates "I totally agree." Questions comprise four aspects representing the personal impressions of treatment benefit, tolerability, convenience of use, and general satisfaction with the treatment [2].…”

Section: Methodsmentioning

confidence: 99%

“…Box 641, Riyadh, Saudi Arabia. 2 Armed Forces Hospitals Southern Region Saudi Arabia, Khamis Mushayt, Saudi Arabia. 3 King Abdulaziz Medical City, NGHA, Riyadh, Saudi Arabia.…”

Section: Fundingmentioning

confidence: 99%

See 1 more Smart Citation

Treatment satisfaction and adherence to medications among multiple sclerosis patients in Saudi Arabia

Alhazzani

Alqahtani

Alamri

et al. 2019

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

Background: Despite the apparent benefits of disease-modifying drug (DMD) use among multiple sclerosis (MS) patients, their rates of adherence are often variable and in some cases are quite low. Aim of the study: To assess medication adherence and its relationship with treatment satisfaction of MS patients in Saudi Arabia Patients and methods: Following a cross-sectional design, 598 adult MS patients were recruited from all tertiary care hospitals in all regions of Saudi Arabia. Patients' medication adherence was assessed using the Arabic version of the eight-item Morisky Medication Adherence Scale (MMAS-8). Treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication. Disease severity was assessed using the Patient-Determined Disease Steps (PDDS). Results: The most used drug was interferon beta-1b (24.1%), while 18.7% were using interferon beta-1a and 17.4% were using fingolimod. Patients' mean PDDS was 2.8 ± 1.9. Only 9.7% were "adherent" to medication. Patients' adherence differed according to their educational level (p < 0.001), their currently received medications (p = 0.032), with those on Fingolimod having the highest adherence (17.3%). Treatment satisfaction was significantly higher among adherent patients (p < 0.023). The main reasons for changing prescribed drugs were the presence of attacks, i.e., response to treatment was substandard (41.8%) and the experienced side effects of used drugs (39.9%). PDDS differed significantly according to patients' treatment adherence only among those receiving interferon beta-1b, with higher mean severity score among those who were adherent (p = 0.002). Conclusions: Medication adherence among MS patients in Saudi Arabia is low. Higher adherence is associated with patients' higher education. The main underlying reasons for changing prescribed drugs are the presence of attacks, substandard response to treatment, or suffering the DMDs' side effects. Medication adherence is associated with higher treatment satisfaction.

show abstract

“…No Brasil, a prevalência varia de acordo com a região geográfica, encontra-se uma maior incidência da doença, nas regiões Sul e Sudeste, porém devido à mistura de raças com influência Europeia gerou um aumento nos estados de São Paulo e Minas Gerais. Estudos definem que são as características genéticas que definem a maior ou menor frequência da EM entre os indivíduos e não o local onde residem (BRUM et al, 2014;FRAGOZO, 2014;SPESSOTO et al, 2016;FERNANDES et al, 2013).…”

Section: Esclerose Múltiplaunclassified

Valores De LDL-C E Consumo Habitual De Ácido Graxo Saturado Esteárico Em Adultos Do Município De João Pessoa/Pb: Um Olhar Para Hipercolesterolemia

Santos¹,

Cosmo²,

Raposo³

et al. 2021

Nutrição Sob a Ótica Teórica E Prática

View full text Add to dashboard Cite

Direitos para esta edição cedidos à Atena Editora pelos autores. Todo o conteúdo deste livro está licenciado sob uma Licença de Atribuição Creative Commons. Atribuição-Não-Comercial-NãoDerivativos 4.0 Internacional (CC BY-NC-ND 4.0).O conteúdo dos artigos e seus dados em sua forma, correção e confiabilidade são de responsabilidade exclusiva dos autores, inclusive não representam necessariamente a posição oficial da Atena Editora. Permitido o download da obra e o compartilhamento desde que sejam atribuídos créditos aos autores, mas sem a possibilidade de alterá-la de nenhuma forma ou utilizá-la para fins comerciais. Todos os manuscritos foram previamente submetidos à avaliação cega pelos pares, membros do Conselho Editorial desta Editora, tendo sido aprovados para a publicação com base em critérios de neutralidade e imparcialidade acadêmica.A Atena Editora é comprometida em garantir a integridade editorial em todas as etapas do processo de publicação, evitando plágio, dados ou resultados fraudulentos e impedindo que interesses financeiros comprometam os padrões éticos da publicação. Situações suspeitas de má conduta científica serão investigadas sob o mais alto padrão de rigor acadêmico e ético.

show abstract

Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis

Cited by 5 publications

References 7 publications

Adherence to disease-modifying therapies in patients with multiple sclerosis

Adherence to disease-modifying therapies in patients with multiple sclerosis

Treatment satisfaction and adherence to medications among multiple sclerosis patients in Saudi Arabia

Valores De LDL-C E Consumo Habitual De Ácido Graxo Saturado Esteárico Em Adultos Do Município De João Pessoa/Pb: Um Olhar Para Hipercolesterolemia

Contact Info

Product

Resources

About